MergerMay 8, 2026, 04:17 PM
Esperion to be Acquired by Essence Parent for $3.16/Share + CVR
AI Summary
Esperion Therapeutics announced an agreement to be acquired by Essence Parent Inc. for $3.16 per share in cash plus one contingent value right (CVR) per share, potentially adding up to $100 million in aggregate upon milestone achievement. This merger is expected to close in Q3 2026. Separately, Esperion completed the acquisition of Corstasis Therapeutics Inc. for $75 million upfront cash, expanding its cardiovascular portfolio with Enbumyst. For Q1 2026, total revenues increased to $80.1 million from $65.0 million year-over-year, while net loss decreased to $25.2 million from $40.5 million.
Key Highlights
- Essence Parent Inc. to acquire Esperion for $3.16 cash per share plus CVRs up to $100M.
- Acquisition of Corstasis Therapeutics Inc. completed for $75M upfront cash, adding Enbumyst.
- Total Revenues for Q1 2026 increased to $80.1 million from $65.0 million in Q1 2025.
- Net Loss for Q1 2026 improved to $25.2 million from $40.5 million in Q1 2025.
- Net Loss per common share was $(0.10) in Q1 2026, compared to $(0.21) in Q1 2025.
- Cash and cash equivalents were $156.2 million at March 31, 2026, down from $167.9 million at Dec 31, 2025.
- Product sales, net, rose to $43.4 million in Q1 2026 from $34.9 million in Q1 2025.
- Collaboration revenue increased to $36.7 million in Q1 2026 from $30.1 million in Q1 2025.